Transforming Large B-Cell Lymphoma (LBCL): CAR T and Novel Agents - Episode 14
Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).